Use of inhaled nitric oxide and oxygen for the treatment of pulmonary hypertension
View Patent ↗Described herein are methods of using inhaled nitric oxide for treating pulmonary hypertension, improving exercise capacity and/or reducing oxygen desaturation in a patient.
1 . A method of reducing oxygen desaturation in a patient with WHO Group 3 pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF), the method comprising:
administering an effective amount of inhaled nitric oxide (iNO) in combination with an effective amount of long-term oxygen therapy (LTOT) to a patient in need thereof, wherein the iNO is administered at a dose of about 50 to about 100 mcg/kg IBW/hr for at least 6 hours a day for at least 4 weeks.
2 . A method of treating WHO Group 3 pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF), the method comprising:
administering an effective amount of inhaled nitric oxide (iNO) in combination with an effective amount of long-term oxygen therapy (LTOT) to a patient in need thereof, wherein the iNO is administered at a dose of about 50 to about 100 mcg/kg IBW/hr for at least 6 hours a day for at least 4 weeks.
3 . A method of improving exercise capacity in a patient with WHO Group 3 pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF), the method comprising:
administering an effective amount of inhaled nitric oxide (iNO) in combination with an effective amount of long-term oxygen therapy (LTOT) to a patient in need thereof, wherein the iNO is administered at a dose of about 50 to about 100 mcg/kg IBW/hr for at least 6 hours a day for at least 4 weeks.
4 . The method of claim 2 , wherein the iNO is administered to the patient during the first half of inspiration.
5 . The method of claim 2 , wherein the iNO is administered for at least 12 hours a day.
6 . The method of claim 2 , wherein the patient has a ventilation-perfusion (V/Q) mismatch.
7 . The method of claim 2 , wherein the iNO is administered for at least 3 months.
8 . The method of claim 2 , wherein the iNO is administered at a dose of about 50 mcg/kg IBW/hr to about 75 mcg/kg IBW/hr.
9 . The method of claim 2 , wherein the iNO is administered at a dose of about 75 mcg/kg IBW/hr.
10 . The method of claim 2 , wherein the administration of iNO provides an average decrease in the reduction of SpO2 during exercise in a group of patients after 16 weeks of iNO administration of at least 1.
11 . The method of claim 2 , wherein the administration of iNO provides an average decrease in the reduction of SpO2 during exercise in a group of patients after 16 weeks of iNO administration of about 3.36.
12 . The method of claim 2 , wherein the administration of iNO provides an average increase in six-minute walk distance (6MWD) exercise in a group of patients after 16 weeks of iNO administration of at least 10 meters.
13 . The method of a claim 2 , wherein the administration of iNO provides an average increase in six-minute walk distance (6MWD) in a group of patients after 16 weeks of iNO administration of about 52.4 meters.